Regular blood tests are vital for managing Sickle Cell Anemia, helping to detect complications early and guide treatment.

Medically reviewed by Soma Mandal, MD Mean corpuscular hemoglobin (MCH) is a measure of the average amount of hemoglobin in ...

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

Amendments in blood work, precisely an unusual soar in hematocrit (HCT) accompanied by a rapid decline in platelet count, signal a concern with the blood's ability to clot and is a proven sign of ...

Amendments in blood work, precisely an unusual soar in hematocrit (HCT) accompanied by a rapid decline in platelet count, signal a concern with the blood's ability to clot and is a proven sign of ...

Choi, Hye Duck, Lee, Seung Woo, SGLT2 Inhibitors increase hemoglobin and hematocrit levels in patients with chronic kidney disease: a systematic review and meta-analysis. J Clin Pharm Ther . 2025 ...

The MCHC blood test measures the concentration of hemoglobin in red blood cells, ... Doctors call this percentage “hematocrit.” Hemoglobin is a protein in red blood cells that’s rich in iron.

Initial results from the SANRECO Phase 1 study were presented in June 2024 and showed that all doses of divesiran substantially reduced phlebotomy frequency and lowered hematocrit (HCT) in 16 ...

Additionally, hematocrit levels were measured at 56.7% in the soccer player and 51% in the Taekwondo athlete, compared with a normal range for adults of 40% to 54% in males and 37% to 47% in females.

Notably, none of the 13 patients entering the trial with HCT levels of 50% or below – 8 well-controlled patients and 5 patients with HCT levels of 46-50% - have required a phlebotomy to date. In all ...

Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients ...